Obesity — Pathophysiology and Management

Hypothalamic Energy Homeostasis Dysfunction

• The hypothalamus serves as the master regulator of energy balance through the arcuate nucleus, which contains two primary neuronal populations: pro-opiomelanocortin (POMC) neurons that suppress appetite and increase energy expenditure, and neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons that stimulate appetite and decrease energy expenditure
• Leptin, an adipokine produced by white adipose tissue in proportion to fat mass, signals energy sufficiency by binding leptin receptors on POMC neurons (promoting satiety) and inhibiting NPY/AgRP neurons
• In obesity, despite elevated leptin levels, leptin resistance develops through multiple mechanisms: impaired leptin transport across the blood-brain barrier via decreased lipoprotein lipase activity, defective leptin receptor signaling via suppressor of cytokine signaling-3 (SOCS-3) overexpression, and chronic low-grade inflammation disrupting JAK-STAT signaling pathways
• This leptin resistance perpetuates paradoxical hypothalamic sensing of energy deficit despite abundant fat stores, driving increased appetite through elevated NPY/AgRP signaling and reduced POMC-mediated anorexigenic neuropeptide α-melanocyte-stimulating hormone (α-MSH) production
• Additionally, ghrelin (produced by gastric fundic cells) levels increase with weight loss or caloric restriction and decrease with obesity, but this normal suppressive signal becomes dysregulated; obesity associates with blunted postprandial ghrelin suppression, perpetuating appetite

Peripheral Insulin Resistance and Metabolic Dysfunction

• Expansion of adipose tissue, particularly visceral (intra-abdominal) adiposity, drives hepatic and peripheral insulin resistance through multiple mechanisms
• Adipose tissue hypertrophy and hyperplasia increase circulating free fatty acids (FFAs), which accumulate in liver and muscle, disrupting insulin signaling by activating serine/threonine kinase pathways (protein kinase C-θ, IκB kinase-β) that phosphorylate and inactivate insulin receptor substrate-1 (IRS-1), preventing downstream phosphatidylinositol 3-kinase (PI3K) activation and glucose transporter-4 (GLUT-4) translocation
• Chronic macrophage infiltration of adipose tissue (M1 polarization) generates pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) that further activate inhibitory serine kinases and impair insulin signaling
• Reduced adiponectin levels (inversely correlated with adipose mass) diminish its insulin-sensitizing effects mediated through AMP-activated protein kinase (AMPK) activation
• Hepatic steatosis develops as excessive FFA uptake overwhelms mitochondrial β-oxidation capacity, leading to triglyceride accumulation, endoplasmic reticulum stress, and hepatic insulin resistance, creating a vicious cycle of hyperinsulinemia and worsening systemic insulin resistance
• Pancreatic β-cell dysfunction eventually develops with chronic hyperinsulinemia, including reduced insulin secretory capacity and impaired glucose-stimulated insulin secretion, progressing toward type 2 diabetes

Chronic Systemic Inflammation and Immune Dysregulation

• Obesity creates a state of chronic, low-grade inflammation ("metaflammation") characterized by elevated circulating pro-inflammatory markers including TNF-α, IL-6, CRP, and PAI-1
• Adipose tissue undergoes pathological remodeling: as adipocytes hypertrophy, they develop hypoxia (due to increased diffusion distances from vasculature), triggering hypoxia-inducible factor-1α (HIF-1α) activation, which promotes inflammatory gene expression and M1 macrophage infiltration
• Toll-like receptor 4 (TLR4) activation by lipopolysaccharide (LPS) from dysbiotic gut microbiota contributes to hepatic and systemic inflammation
• Increased circulating damage-associated molecular patterns (DAMPs) from adipocyte necrosis activate pattern recognition receptors on innate immune cells, perpetuating inflammatory signaling
• This inflammatory milieu contributes to atherosclerotic plaque development, endothelial dysfunction, and vascular stiffness

Adipose Tissue Dysfunction and Altered Metabolic Signature

• White adipose tissue (WAT) normally functions as a flexible metabolic reservoir, storing excess energy as triglycerides during fed states and releasing FFAs during fasting; in obesity, this becomes dysregulated
• Expanded visceral adipose tissue exhibits reduced expression of protective genes (e.g., adiponectin, IL-10) and increased expression of pathogenic factors including monocyte chemoattractant protein-1 (MCP-1), driving immune cell recruitment
• Impaired mitochondrial function within adipocytes reduces oxidative capacity and ATP production, exacerbating metabolic inflexibility—the inability to efficiently switch between fat and carbohydrate oxidation
• Reduced brown adipose tissue (BAT) activity in obesity diminishes thermogenesis; cold-induced sympathetic activation normally triggers uncoupling protein 1 (UCP1) expression in brown adipocytes, dissipating energy as heat, but this pathway is suppressed in obesity
• Altered gut microbiota composition (dysbiosis) with reduced bacterial diversity and shifted Firmicutes-to-Bacteroidetes ratio contributes to increased intestinal permeability ("leaky gut"), LPS translocation, and reduced production of short-chain fatty acids (butyrate) that normally support barrier function

Genetic Predisposition and Epigenetic Modifications

• Monogenic obesity syndromes, though rare, illuminate key pathways: mutations in leptin (LEP), leptin receptor (LEPR), POMC, PCSK1 (prohormone convertase 1), PTEN, and TrkB cause severe, early-onset obesity with hyperphagia
• More commonly, polygenic obesity involves hundreds of genetic variants of small effect; genome-wide association studies (GWAS) have identified >250 loci associated with BMI, many mapping to hypothalamic regulatory regions
• FTO (fat mass and obesity-associated) polymorphisms show the strongest association with BMI; risk alleles correlate with increased hunger perception and reduced satiety signaling
• Epigenetic modifications (DNA methylation, histone acetylation) in metabolic tissues are altered by obesity and may be partially reversible with weight loss, representing a mechanism for transgenerational transmission of metabolic risk
• Gene-environment interactions are critical: genetic predisposition is necessary but insufficient; obesogenic environments (high-calorie food availability, sedentary lifestyles, sleep deprivation, chronic stress) activate genetic susceptibility

Central Mechanisms Driving Increased Energy Intake

• Beyond appetite regulation, obesity involves dysregulation of reward circuitry in the ventral tegmental area and nucleus accumbens; high-calorie, palatable foods trigger dopamine release similar to addictive substances
• Sensitization of reward pathways occurs with repeated high-calorie food exposure, requiring greater intake to achieve satiety—analogous to addiction tolerance
• Impaired prefrontal cortex activity reduces inhibitory control over food-seeking behaviors, particularly in stress states

Primary (Non-Syndromic) Obesity

• Accounts for >95% of obesity cases and results from gene-environment interactions; no single identifiable endocrine or genetic cause, but rather multifactorial combination of dietary excess (particularly refined carbohydrates and ultra-processed foods with high energy density and low satiety), physical inactivity, sleep deprivation (<7 hours nightly increases obesity risk by 30%), chronic psychological stress (elevates cortisol and promotes visceral fat deposition and appetite), and genetic predisposition (twin studies show 70-80% heritability)
• Environmental factors include food marketing, portion size inflation, reduced energy expenditure from automation and sedentary work, and built environments discouraging physical activity

Secondary Obesity Due to Endocrine Disorders

• Hypothyroidism reduces metabolic rate through decreased mitochondrial oxidative capacity and β-adrenergic responsiveness; TSH >5 mIU/L correlates with weight gain of 5-10 kg
• Cushing's syndrome promotes visceral adiposity through glucocorticoid-mediated abdominal fat depot expansion, impaired glucose utilization, and increased appetite; characterized by rapid weight gain, proximal weakness, and purple striae
• Polycystic ovary syndrome (PCOS) associates with insulin resistance and hyperandrogenism driving central obesity in reproductive-age women; present in 30-40% of obese women of childbearing age
• Hypogonadism in males reduces testosterone-mediated lipolysis and increases appetite; androgen deficiency states correlate with preferential visceral fat accumulation
• Growth hormone deficiency reduces basal metabolic rate and visceral adiposity; seen in hypopituitarism or post-pituitary surgery
• Hypothalamic amenorrhea from tumors (e.g., craniopharyngioma), inflammatory conditions (sarcoidosis), or trauma can cause severe obesity through leptin-responsive hypothalamic dysfunction

Medication-Induced Obesity

• Glucocorticoids (prednisone, dexamethasone)—most notable contributors; increase appetite, promote visceral fat deposition, and impair glucose tolerance; >5 mg/day prednisone equivalent correlates with weight gain
• Antipsychotics: olanzapine and clozapine cause severe weight gain (5-10 kg annually) through dopamine D2 receptor antagonism and 5-HT2C receptor effects; alternatives include aripiprazole with minimal weight effect
• Antidepressants: tricyclic antidepressants (amitriptyline), paroxetine (selective serotonin reuptake inhibitors), and mirtazapine promote weight gain
• Anticonvulsants: valproate, gabapentin
• Insulin and sulfonylureas cause weight gain through increased insulin secretion and peripheral glucose utilization driving storage rather than oxidation
• Beta-blockers reduce sympathetically-mediated thermogenesis and may promote weight gain
• Oral contraceptives and hormone replacement therapy increase appetite through estrogen effects on hypothalamic neuropeptides

Monogenic/Syndromic Obesity

• Congenital leptin deficiency (LEP mutations)—presents with severe early-onset obesity, hyperphagia starting in infancy, hypogonadism, and immune dysfunction; treatable with recombinant leptin (metreleptin)
• Leptin receptor mutations (LEPR)—phenotypically similar to leptin deficiency but leptin resistance; unresponsive to leptin therapy
• POMC/PCSK1 deficiency—presents with severe obesity, red hair, pale skin, adrenal insufficiency (ACTH deficiency), and hypogonadism
• MC4R mutations—autosomal dominant; presents with severe, early-onset obesity, increased linear growth, and hyperphagia; partially responsive to melanocortin agonists
• PTEN hamartoma tumor syndrome—inherited PTEN mutations cause childhood-onset obesity, macrocephaly, and increased cancer risk
• Bardet-Biedl syndrome—autosomal recessive; ciliopathy presenting with obesity, retinitis pigmentosa, polydactyly, renal dysfunction, and cognitive impairment
• Prader-Willi syndrome—loss of paternal 15q11-q13 imprinting causes hypotonia in infancy, followed by hyperphagia and severe obesity in childhood, developmental delay, hypogonadism
• Melanocortin 3 receptor (MC3R) deficiency—rare; early-onset obesity with increased linear growth

Metabolic/Nutritional Factors

• High glycemic index diet lacking fiber promotes rapid glucose spikes and reactive hyperinsulinemia, driving fat storage
• High fructose intake bypasses satiety signals (fructose does not stimulate leptin secretion) and promotes hepatic lipogenesis
• Nutrient deficiencies including vitamin D insufficiency (elevated PTH increases intracellular calcium, promoting lipogenesis), iron deficiency, and magnesium deficiency correlate with obesity risk
• Microbiota dysbiosis from antibiotic exposure, low-fiber diet, or pathogenic infection reduces butyrate-producing commensals and increases pathogenic gram-negative bacteria

Sociodemographic Risk Factors

• Socioeconomic disadvantage correlates with obesity due to limited access to nutritious foods, increased stress, and reduced activity opportunities
• Racial/ethnic disparities: non-Hispanic Black and Hispanic individuals in the U.S. have higher obesity prevalence (49-51%) compared to non-Hispanic White individuals (41%), reflecting both genetic ancestry and environmental/social factors
• Female gender: women have slightly higher obesity prevalence than men globally, influenced by reproductive hormones and post-menopausal increased visceral deposition
• Age: obesity prevalence increases through middle age, with peak prevalence in ages 40-59 years

Cardinal Metabolic Manifestations

Increased Body Weight and Altered Body Composition

• Primary presenting symptom; excessive fat mass accumulation most prominent in central/visceral distribution, though subcutaneous expansion also occurs
• Patients often report gradual weight gain over years to decades, with acceleration during high-stress periods, life transitions (college, marriage, parenthood), or following major dietary shifts
• Altered body composition includes reduced lean muscle mass percentage despite absolute muscle mass preservation due to increased load-bearing; this paradoxical "sarcopenic obesity" impairs functional capacity

Dyslipidemia

• Hypertriglyceridemia (often >200 mg/dL) results from increased hepatic VLDL production driven by excess FFAs; fasting triglycerides often elevated out of proportion to total cholesterol
• Reduced HDL cholesterol (<40 mg/dL in men, <50 mg/dL in women) reflects dysfunctional reverse cholesterol transport
• Elevated LDL particle number (particularly small, dense LDL subfractions) despite normal or near-normal LDL-C due to triglyceride-mediated particle composition shifts; these atherogenic particles are poorly detected by standard lipid panels

Impaired Glucose Homeostasis and Type 2 Diabetes

• Impaired fasting glucose (100-125 mg/dL) or impaired glucose tolerance on 2-hour OGTT (140-199 mg/dL) precedes overt diabetes
• Type 2 diabetes develops in 50% of obese adults by age 60; presents insidiously with polyuria, polydipsia, and fatigue only after significant hyperglycemia (often HbA1c >8-9%)
• Hyperinsulinemia (fasting insulin >12 mIU/L) reflects compensatory β-cell response to peripheral insulin resistance

Hypertension

• Develops in 55-60% of obese adults; mechanisms include volume expansion from renal sodium retention, sympathetic nervous system activation, endothelial dysfunction, and vascular stiffening from chronic inflammation
• Often resistant to single-agent therapy; presents as Stage 2 hypertension (≥140/90 mmHg) requiring multiple antihypertensive agents
• Salt-sensitive hypertension particularly prominent, exacerbated by processed food consumption

Systemic Inflammation and Prothrombotic State

• Markedly elevated CRP (often >5 mg/L; normal <3 mg/L), often exceeding levels in acute infection without fever or acute phase symptoms
• Elevated fibrinogen and D-dimer indicate systemic thrombotic tendency; elevated PAI-1 impairs fibrinolysis
• Elevated prothrombin time parad

Step 1 — anthropometric screening

• BMI (weight in kg ÷ height in m²): the initial and, in practice, the diagnostic test. Overweight 25–29.9, class I obesity 30–34.9, class II 35–39.9, class III ≥40 kg/m². The USPSTF recommends screening all adults with BMI and offering or referring those with BMI ≥30 to intensive multicomponent behavioral intervention.
• Waist circumference: measured at the iliac crest; captures visceral adiposity, the metabolically active compartment, which BMI cannot distinguish from muscle. Elevated at >40 in (102 cm) in men and >35 in (88 cm) in women, and this is the abdominal-obesity criterion in the harmonized metabolic syndrome definition (any 3 of: elevated waist, triglycerides, low HDL, elevated blood pressure, elevated fasting glucose).
• Lower thresholds in South and East Asian patients: WHO-endorsed cut-points define overweight at BMI ≥23 and obesity at ≥27.5 kg/m², because visceral fat and insulin resistance appear at lower total mass.

Step 2 — body-composition confirmation (rarely needed clinically)

• DXA, air-displacement plethysmography, or hydrodensitometry quantify true fat mass and are the reference standards when BMI misclassifies (muscular athletes, sarcopenic elderly). Bioelectrical impedance is convenient but hydration-dependent.

Step 3 — exclude secondary causes and stage the disease

• Targeted endocrine testing: TSH for hypothyroidism; late-night salivary cortisol, 1 mg overnight dexamethasone suppression, or 24-h urinary free cortisol only when proximal myopathy, violaceous striae, easy bruising are present. Do not screen every obese patient for Cushing syndrome.
• Comorbidity panel: fasting glucose/HbA1c (ADA Standards of Care support screening all adults with overweight/obesity plus a risk factor), fasting lipids, ALT/AST with FIB-4 for steatotic liver disease per AASLD, blood pressure, and STOP-BANG screening with polysomnography for obstructive sleep apnea.
• Edmonton Obesity Staging System (EOSS, 0–4): grades functional, medical, and psychological burden and predicts mortality better than BMI alone — the named staging tool examiners may reference.

Foundation for every patient (first-line)

• Comprehensive lifestyle intervention: a sustained energy deficit (commonly ~500–750 kcal/day), ≥150 min/week of moderate-intensity activity, and high-intensity behavioral counseling — the USPSTF-endorsed core, and the base on which all drug and surgical therapy is layered.
• Deprescribe obesogenic drugs: substitute aripiprazole or ziprasidone for olanzapine/clozapine, metformin/GLP-1 agents for sulfonylureas or insulin where feasible, and taper glucocorticoids. Treat identified secondary causes (levothyroxine for hypothyroidism) — but do not expect thyroid replacement to normalize weight.

Pharmacotherapy — indicated at BMI ≥30, or ≥27 with a weight-related comorbidity (Endocrine Society and AACE)

• Incretin-based agents (preferred): GLP-1 receptor agonist semaglutide or dual GIP/GLP-1 agonist tirzepatide; they slow gastric emptying and act on hypothalamic POMC neurons to restore satiety signaling, producing the largest non-surgical weight loss. Liraglutide is an alternative.
• Second-line oral options: sympathomimetic/anticonvulsant combination phentermine–topiramate; naltrexone–bupropion (disinhibits POMC neurons and blunts reward-driven eating); intestinal lipase inhibitor orlistat; short-term phentermine alone.
• Contraindicated: all weight-loss pharmacotherapy in pregnancy (topiramate is teratogenic — oral clefts); GLP-1/GIP agents with personal or family history of medullary thyroid carcinoma or MEN2, and with prior pancreatitis; naltrexone–bupropion with seizure disorder, eating disorders, or chronic opioid use; phentermine with uncontrolled hypertension, hyperthyroidism, or glaucoma.

Definitive therapy — metabolic and bariatric surgery

• The 2022 ASMBS/IFSO indications endorse surgery at BMI ≥35 regardless of comorbidity, and at BMI 30–34.9 with metabolic disease; the ADA similarly supports metabolic surgery for type 2 diabetes at BMI ≥30 (≥27.5 in Asian Americans).
• Sleeve gastrectomy (restrictive, reduces ghrelin-producing fundus) and Roux-en-Y gastric bypass (restrictive plus incretin-mediated) are the standard operations. Choose bypass when GERD or difficult diabetes dominates, since sleeve worsens reflux.
• Untreated substance use disorder, uncontrolled psychiatric illness, and inability to comply with lifelong micronutrient supplementation are relative contraindications.

Cardiometabolic and vascular

• Type 2 diabetes and atherosclerotic cardiovascular disease: FFA- and cytokine-driven IRS-1 serine phosphorylation causes insulin resistance; β-cell exhaustion signals the transition, marked by rising HbA1c despite hyperinsulinemia.
• HFpEF and atrial fibrillation: plasma volume expansion, epicardial fat, and myocardial fibrosis produce exertional dyspnea with preserved EF and elevated natriuretic peptides (which may be lower than expected in obesity — a classic trap).
• Venous thromboembolism: elevated PAI-1 and fibrinogen with venous stasis; sudden dyspnea with hypoxemia is an emergency.

Respiratory

• Obstructive sleep apnea from parapharyngeal fat: witnessed apneas, morning headache, resistant hypertension.
• Obesity hypoventilation syndrome: daytime hypercapnia with elevated serum bicarbonate; acute hypercapnic respiratory failure is an emergency requiring noninvasive positive-pressure ventilation.

Hepatic, renal, and gynecologic

• Metabolic dysfunction–associated steatotic liver disease progressing to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma; suspected on elevated ALT and an abnormal FIB-4 (AASLD).
• Obesity-related glomerulopathy: hyperfiltration-induced secondary focal segmental glomerulosclerosis presenting with proteinuria and typically without full nephrotic syndrome.
• PCOS, anovulatory infertility, and endometrial hyperplasia/carcinoma from peripheral aromatization of androgens to unopposed estrogen. Obesity also raises risk of postmenopausal breast, colorectal, esophageal adenocarcinoma, renal, and pancreatic cancer.
• Idiopathic intracranial hypertension: headache, papilledema, and pulsatile tinnitus in a young woman — vision loss is the emergency.
• Cholelithiasis, osteoarthritis, gout, GERD, and depression complete the picture.

Treatment-related

• GLP-1/GIP agents: nausea, gallstones from rapid weight loss, pancreatitis (emergency), and delayed gastric emptying causing retained gastric contents at anesthesia induction.
• Orlistat: steatorrhea, fat-soluble vitamin (A, D, E, K) deficiency, and calcium-oxalate nephrolithiasis.
• Post-bariatric: anastomotic leak — persistent tachycardia is the earliest sign and is an emergency; internal hernia with closed-loop obstruction after Roux-en-Y (emergency, CT may be nondiagnostic); dumping syndrome; marginal ulcer; post-bypass hyperinsulinemic hypoglycemia; and iron, B12, folate, calcium/vitamin D, and thiamine deficiency — persistent vomiting can precipitate Wernicke encephalopathy.

• Leptin is HIGH, not low, in common obesity: the defect is leptin resistance (impaired transport, SOCS-3 induction). Metreleptin works only in congenital leptin deficiency or lipodystrophy — giving leptin to a garden-variety obese patient is the classic distractor.
• Tachycardia after gastric bypass is an anastomotic leak until proven otherwise: a heart rate above ~120 with abdominal pain, even with a benign exam and normal labs, mandates urgent imaging or return to the OR. Do not wait for fever or peritonitis.
• Postoperative persistent vomiting → give thiamine before glucose: dextrose-first precipitates Wernicke encephalopathy (confusion, ophthalmoplegia, ataxia). Chronic B12 and iron deficiency follow bypass because the duodenum and acid-producing stomach are bypassed.
• Sleeve gastrectomy worsens GERD; Roux-en-Y improves it: a patient with obesity plus severe reflux or Barrett esophagus should get bypass. Bypass also gives the greatest diabetes remission.
• MC4R mutation is the most common monogenic cause of obesity (autosomal dominant, tall stature, hyperphagia). Contrast Prader-Willi (neonatal hypotonia and poor feeding, then hyperphagia; loss of paternal 15q11-q13) with Bardet-Biedl (retinitis pigmentosa, polydactyly, renal anomalies).
• Young woman with obesity, headache, papilledema, and normal neuroimaging = idiopathic intracranial hypertension: next step is LP after imaging showing elevated opening pressure; treat with weight loss and acetazolamide.
• Never blame all the weight on hypothyroidism: TSH elevation typically explains only modest gain, largely fluid — levothyroxine is not weight-loss therapy and is contraindicated for that purpose.
• Check the GLP-1 contraindication: personal or family history of medullary thyroid carcinoma or MEN2 rules out semaglutide, liraglutide, and tirzepatide; all obesity drugs are contraindicated in pregnancy.